Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable resistance from managed care entities. Such organizations are often creating limitations to reimbursement, such as steep expense restrictions and prior authorization check here tha